Cargando…
Drug super spender tsunami: An integrated medical and pharmacy benefits assessment
BACKGROUND: As new rare-disease drug therapy, gene therapies, and high-priced cancer drugs receive US Food and Drug Administration approval, there is an increasing potential for drug super spender individuals with more than $250,000 annual drug cost. OBJECTIVE: To categorize all members in a large,...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373036/ https://www.ncbi.nlm.nih.gov/pubmed/36282927 http://dx.doi.org/10.18553/jmcp.2022.28.11.1200 |